Psychedelic Business Spotlight – January 21
Catch up on some of the biggest psychedelic business developments that unfolded in the last week.
health canada
Canada Green Lights Country’s Third Clinical Psilocybin Study
The trial will build on Diamond Therapeutic’s previous animal research that demonstrated how non-hallucinogenic doses of psilocybin hold the potential to treat psychiatric disorders, including anxiety and depression.
End of content
End of content